Skip to main content
Quest Diagnostics

Cost-effectiveness of Nucleic Acid Amplification Testing to Guide Treatment for Vaginitis: A Decision-Modeling Analysis

Cost-effectiveness of Nucleic Acid Amplification Testing to Guide Treatment for Vaginitis: A Decision-modeling Analysis

Authors: Li Y, Feringa BL, Devlin JJ.

Citation: Diagn Microbiol Infect Dis. 2020 Jun 25;98(2):115119. doi: 10.1016/j.diagmicrobio.2020.115119. Online ahead of print.

Specialties: Women's Health, OB/GYN, Infectious disease

Download key summary

Related content

Vaginitis Polymerase Chain Reaction (PCR) Testing and Occurrence of Mixed Infections: Results From a Large US Clinical Laboratory
Publication
Trichomonas vaginalis detection in urogenital specimens from symptomatic and asymptomatic men and women using the cobas TV/MG test
Test FAQ
SureSwab® Advanced Vaginitis, TMA
Test FAQ
SureSwab® Advanced Candida Vaginitis (CV), TMA
Test FAQ
SureSwab® Advanced Vaginitis Plus, TMA

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.